way252623
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2006 (NCT00385489)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- LXR-alphaAGONIST
NR1H3 agonist
project terminated in 2007, reason quoted as "unfavorable profile for further development" (http://www.karobio.com/investormedia/pressreleaser/pressrelease?pid=3005162)
- LXR-betaAGONIST
NR1H2 agonist
project terminated in 2007, reason quoted as "unfavorable profile for further development" (http://www.karobio.com/investormedia/pressreleaser/pressrelease?pid=3005162)
Chemistry & pharmacology
Loading structure…
SMILES
Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1- Mol. weight
- 422.78 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL456237 ↗
Also known as
- 2-(2-chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2h-indazole
- lxr623
- lxr 623
- lxr-623
- lxr-623
- lxr-623
- lxr-623
- way252623
- way 252623
- way-252623
- way-252623
- way-252623
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00379860 | Phase 1 | Oct 1, 2006 | Pfizer, Wyeth |
| NCT00366522 | Phase 1 | Aug 1, 2006 | Pfizer, Wyeth |
| NCT00385489 | Phase 1 | Aug 1, 2006 | Pfizer, Wyeth |
Showing 3 of 3 trials
Page 1 / 1